Join Dr. John Ross as he moderates a discussion about:
In an AV DCB study1
In an AV DCB study.
Results from the IN.PACT™ AV Access Clinical Trial found in the IN.PACT™ AV drug-coated balloon (DCB) Instructions for Use (IFU).
Thamer M, Lee TC, Wasse H, et al. Medicare Costs Associated With Arteriovenous Fistulas Among US Hemodialysis Patients. Am J Kidney Dis. July 1, 2018;72(1):10-18.
Target Lesion Primary Patency Rate based on KM estimates: Defined as freedom from clinically driven target lesion revascularization (CD-TLR) or access circuit thrombosis calculated at 180 days.
Access Circuit Primary Patency based on KM estimates: Defined as freedom from reintervention in the access circuit or access circuit thrombosis calculated at 180 days.
Reduction in reinterventions: Defined as the number of interventions required to maintain target lesion primary patency calculated at 210 days.